DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/9ec7ab/antivirals_market) has announced the addition of the "Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and Hepatitis C Markets" report to their offering.
Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and Hepatitis C Markets. It provides in-depth analysis of the unmet needs, drivers and barriers that affect the global dermatology therapeutics market. The report analyzes the markets for dermatology therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts..
The HIV Market will Grow Moderately Driven by Decreased Mortality and Increased Usage; Growth Will be Impacted by Patent Expiries
The HIV market is a growing market dominated by the US. The growth rate is likely to decline from 2012 onwards due to the impact of patent expiry of key drugs. However, migration to new branded drugs is likely to minimize the impact of generics, which currently account for approximately 8% of the market. The global HIV therapeutics market is expected to grow at a CAGR of 4.5% from $13 billion in 2008 and to $17 billion in 2016. The market is driven by an increase in the treatment-seeking rate as well as the introduction of newer drugs such as Atripla as part of HAART. The HIV market is growing at a slower rate compared to previous years. This is primarily due to the patent expiry of major drugs such as Sustiva and Combivir in 2012. Some other drugs such as Epivir, Epzicom, Trizivir, Ziagen, Invirase and Lexiva are going off patent in 2009 and 2010. However the impact of patent expiration will be offset by the increased use of newer drugs which are more effective in tackling the progression of the disease.
The sales of new drugs such as Atripla have increased by a CAGR of 136% over the last three years; other drugs such as Trizivir, Relenza and Epivir have declined by a CAGR of 11%, 21% and 17% respectively. Approximately 1.5 million people infected with HIV received antiretroviral treatment (ART) in 2008 for an average cost of therapy of $8,300 per year. The number of people taking treatment for HIV is increasing at a slow rate of 2.2% per year. In addition, the average annual cost of therapy for ART is forecast to increase at a higher rate over the next 3-4 years with an expected price decline in 2013 onwards due to a series of patent expirations. However, the market is again expected to increase slightly towards the end of 2016 due to a shift to newer drugs as well as the impact of inflation. Additionally, the late stage pipeline drugs such as Rilpivirine by Tibotec Pharmaceuticals and Vicriviroc by Schering-Plough are expected to enter market during 2009-2016 and will positively impact the market. As a result, the HIV market value is going to see a moderate increase over the time period 2009-2016.
Scope:
- Data and analysis on HIV, Hepatitis, Herpes and Influenza therapeutics market in the leading geographies of the world the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the diabetes therapeutics market from 2001 to 2009, with forecasts to 2016.
- Market Data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
- Key drivers and restraints that have had a significant impact on the market.
- Competitive landscape of the global antivirals therapeutics market including top companies benchmarking. The key companies studied in this report are Novo Nordisk, Sanofi-Aventis, Takeda Pharmaceuticals, Merck, GlaxoSmithKline, Roche, Bristol Myers Squibb and Gilead.
Reasons to buy:
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might probably fill their portfolio gaps.
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with increased efficiency and better safety profiles.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
Key Topics Covered:
1. Table of Contents 1.1 List of Tables 1.2 List of Figures
2 Global Antivirals Market: Introduction 2.1 GBI Research Report Guidance
3 Global HIV Therapeutics Market: Overview 3.1 Disease Overview 3.2 Market Overview
4 Global HIV Therapeutics Market: Market Characterization 4.1 Market Forecasts 4.2 Annual Cost of Therapy 4.3 Usage Patterns 4.4 HIV Therapeutics Market: Drivers and Restraints 4.5 Market Drivers 4.6 Market Restraints
5 Global HIV Therapeutics Market: The US Market 5.1 Market Forecasts 5.2 Annual Cost of Therapy 5.3 Usage Patterns
6 Global HIV Therapeutics Market: Europe Market 6.1 Market Forecasts 6.2 Annual Cost of Therapy 6.3 Usage Patterns
7 Global HIV Therapeutics Market: Japan Market 7.1 Market Forecasts 7.2 Annual Cost of Therapy 7.3 Usage Patterns
8 Global HIV Therapeutics Market: Major Drug Classes 8.1 Different Classes of Drugs 8.2 Pipeline Analysis
9 Global Hepatitis Therapeutics Market: Market Overview 9.1 Introduction 9.2 Revenue Forecasts for the Global Hepatitis Therapeutics Market 9.3 Hepatitis Market Drivers 9.4 Hepatitis Market Restraints 9.5 Generic Share in the Global Hepatitis Market
10 Global Hepatitis Market: Therapeutic Landscape 10.1 Introduction 10.2 Overview of Hepatitis A and B Vaccines Market 10.3 Hepatitis B Market 10.4 Hepatitis C Market
11 Global Hepatitis Market: Geographical Landscape 11.1 Geographical Break-up 11.2 The US 11.3 Top Five Countries in Europe 11.4 Japan 11.5 Global Hepatitis Vaccines and Therapeutics Market: Pipeline Analysis 11.6 Introduction
12 Herpes Simplex Therapeutics Market: Market Characterization 12.1 Overview 12.2 Herpes Simplex Therapeutics Market Size 12.3 Herpes Simplex Therapeutics Market Forecast and CAGR 12.4 Drivers and Barriers for the Herpes Simplex Therapeutics Market 12.5 Herpes Simplex Therapeutics Market: Competitive Assessment 12.6 Overview 12.7 Strategic Competitor Assessment 12.8 Product Portfolio for Major Marketed Products in the Herpes Simplex Therapeutics Market
13 Herpes Simplex Therapeutics Market: Pipeline Assessment 13.1 Overview 13.2 Herpes Simplex Therapeutics Promising Drugs under Clinical Development 13.3 Molecule Profiles for Promising Drugs under Clinical Development 13.4 Herpes Simplex Therapeutics Market Pipeline Assessment by Mechanism of Action 13.5 Herpes Simplex Therapeutics Market Pipeline Assessment by Clinical Phase of Development
14 Global Influenza Therapeutics Market: Overview 14.1 Disease Overview 14.2 Influenza 14.3 Market Overview
15 Global Influenza Therapeutics Market: Market Characterization 15.1 Market Forecasts 15.2 Annual Cost of Therapy 15.3 Usage Patterns
16 Global Influenza Therapeutics Market: The US Market 16.1 Market Forecasts 16.2 Annual Cost of Therapy 16.3 Usage Patterns
17 Global Influenza Therapeutics Market: Europe Market 17.1 Market Forecasts 17.2 Annual Cost of Therapy 17.3 Usage Patterns
18 Global Influenza Therapeutics Market: Japan Market 18.1 Market Forecasts 18.2 Annual Cost of Therapy 18.3 Usage Patterns
19 Pipeline Analysis
20 Antivirals Market- Competitive Landscape 20.1 Global HIV/AIDs Market: Competitive Landscape 20.2 Major Company Profiles 20.3 Global Hepatitis Therapeutics Market- Competive Landcape 20.4 Major Company Profiles 20.5 Global Herpes Simplex Market: Competitive Landscape 20.6 Major Company Profiles
21 Global Antivirals Therapeutics Market: Strategic Consolidations 21.1 Global HIV/AIDS Market 21.2 Global Hepatitis Market 21.3 Global Herpes Market 21.4 Global Influenza Therapeutics Market
22 Antivirals Market: Appendix 22.1 Market Definitions 22.2 Abbreviations 22.3 Research Methodology 22.4 Contact Us 22.5 Disclaimer 22.6 Sources
For more information visit http://www.researchandmarkets.com/research/9ec7ab/antivirals_market